

**TDMs No.** 20311 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**

**Date Report Requested:** 06/29/2009

**Test Type:** CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

**Time Report Requested:** 16:30:20

**Route:** IN-UTERO

**CAS Number:** AIDSTHERAPEU

**First Dose M/F:** NA / 07/10/03

**Species/Strain:** MICE/B6C3F1/NCTR

**Lab:** NCTR

**C Number:** C20311  
**Lock Date:** 12/01/2008  
**Cage Range:** ALL  
**Date Range:** ALL  
**Reasons For Removal:** ALL  
**Removal Date Range:** ALL  
**Treatment Groups:** Include ALL  
**Study Gender:** Female  
**TDMSE Version:** 2.1.0

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
<b>Disposition Summary</b>						
Animals Initially in Study	48	47	48	48	51	48
Early Deaths						
Moribund Sacrifice	8	7	3	4	8	9
Natural Death	2	1	3	3	2	3
Survivors						
Moribund Sacrifice		3	2	1	2	2
Natural Death		1			1	
Terminal Sacrifice	37	28	38	35	35	32
Harvest	1	7	2	5	3	2
Animals Examined Microscopically	48	47	47	48	51	48

## ALIMENTARY SYSTEM

Esophagus	(47)	(47)	(46)	(48)	(50)	(47)
Gallbladder	(46)	(45)	(44)	(46)	(48)	(45)
Cyst		1 [1.0]	2 [2.0]			
Degeneration, Hyaline						
Infiltration Cellular, Lymphocyte			1 [1.0]			1 [1.0]
Inflammation, Chronic		1 [2.0]				
Intestine Large, Cecum	(46)	(46)	(46)	(46)	(49)	(46)
Hyperplasia, Lymphoid	2 [2.0]		2 [2.0]	1 [2.0]	2 [2.0]	1 [2.0]
Serosa, Hyperplasia						
Intestine Large, Colon	(46)	(46)	(46)	(46)	(50)	(46)
Intestine Large, Rectum	(46)	(46)	(46)	(46)	(50)	(46)
Hyperplasia, Lymphoid				1 [2.0]		1 [2.0]
Intestine Small, Duodenum	(46)	(47)	(45)	(45)	(49)	(45)
Diverticulum			1 [4.0]			
Intestine Small, Ileum	(46)	(46)	(46)	(46)	(50)	(46)
Hyperplasia, Lymphoid	1 [2.0]		2 [1.5]			1 [2.0]
Inflammation, Chronic Active						
Intestine Small, Jejunum	(46)	(45)	(46)	(46)	(48)	(46)
Hyperplasia, Lymphoid	1 [2.0]		1 [4.0]			
Epithelium, Hyperplasia						
Liver	(47)	(46)	(46)	(48)	(50)	(47)
Angiectasis		1 [1.0]			1 [2.0]	
Autolysis						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Basophilic Focus	2	2	3	7	3	2
Basophilic Focus, Multiple					1	
Clear Cell Focus				1	2	
Congestion	1 [2.0]				1 [2.0]	
Cyst						
Cyst Multilocular		1				
Deformity						
Eosinophilic Focus	2	1		2	1	1
Eosinophilic Focus, Multiple			1			
Fatty Change						
Hematocyst					1	
Hematopoietic Cell Proliferation	1 [3.0]	2 [2.5]			1 [4.0]	
Hemorrhage	1 [4.0]					
Hepatodiaphragmatic Nodule				1		
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	13 [1.1]	13 [1.1]	12 [1.1]	13 [1.4]	17 [1.3]	10 [1.1]
Inflammation, Chronic Active	2 [1.0]	2 [2.0]	3 [1.0]	2 [1.0]	2 [1.5]	2 [1.0]
Mineralization						
Mixed Cell Focus		2	1	1	2	2
Necrosis	2 [2.5]	5 [2.6]			1 [4.0]	1 [4.0]
Tension Lipidosis	11 [1.5]	2 [1.5]	5 [1.0]	6 [1.7]	6 [1.7]	8 [1.5]
Vacuolization Cytoplasmic	18 [1.6]	23 [1.8]	19 [1.5]	16 [1.9]	28 [1.9]	21 [1.7]
Mesentery	(8)	(4)	(11)	(6)	(7)	(11)
Cyst			1 [4.0]			
Hematocyst					1	
Hemorrhage			2 [4.0]	2 [3.5]	1 [2.0]	1 [4.0]
Infiltration Cellular, Lymphocyte				1 [3.0]	1 [3.0]	
Fat, Necrosis	8 [3.8]	3 [3.3]	11 [3.5]	5 [3.8]	6 [3.7]	9 [3.8]
Pancreas	(46)	(46)	(46)	(48)	(49)	(46)
Cyst			1 [4.0]			
Cytoplasmic Alteration	1 [1.0]					
Edema			1 [2.0]			
Infiltration Cellular, Lymphocyte	18 [1.2]	15 [1.3]	13 [1.1]	18 [1.2]	19 [1.3]	16 [1.2]
Inflammation, Chronic Active			1 [4.0]			
Mineralization						
Necrosis			1 [4.0]			
Acinus, Degeneration	1 [2.0]	1 [3.0]	2 [1.5]		1 [1.0]	1 [1.0]
Duct, Dilatation						
Fat, Necrosis			1 [3.0]			
Salivary Glands	(47)	(45)	(46)	(48)	(50)	(46)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Infiltration Cellular, Lymphocyte Polyarteritis	38 [1.6]	40 [1.4]	39 [1.6]	39 [1.4]	46 [1.6]	38 [1.6]
Acinus, Degeneration		1 [2.0]		1 [2.0]		
Stomach, Forestomach	(46)	(47)	(45)	(47)	(50)	(46)
Hyperkeratosis				2 [2.0]		
Hyperplasia						
Inflammation, Chronic Active					1	
Keratin Cyst						
Ulcer						
Epithelium, Hyperplasia		1 [2.0]		1 [2.0]		2 [2.0]
Stomach, Glandular	(46)	(46)	(45)	(46)	(48)	(46)
Degeneration, Hyaline				2 [3.0]		
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic Active			1 [2.0]	2 [2.5]		2 [2.0]
Mineralization		1 [1.0]				
Epithelium, Hyperplasia			1 [2.0]	2 [3.0]		2 [3.0]
<b>CARDIOVASCULAR SYSTEM</b>						
Blood Vessel	(48)	(46)	(46)	(48)	(49)	(45)
Heart	(47)	(47)	(46)	(48)	(50)	(48)
Cardiomyopathy					1 [2.0]	
Inflammation, Suppurative						
Inflammation, Chronic Active						
Mineralization					1 [2.0]	
Necrosis						1 [1.0]
Polyarteritis	1 [2.0]					
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(47)	(47)	(46)	(47)	(50)	(47)
Accessory Adrenal Cortical Nodule	4	4	3	1	1	2
Angiectasis		1 [2.0]				
Cyst			1 [1.0]			2 [1.5]
Hypertrophy						1 [2.0]
Vacuolization Cytoplasmic	6 [3.0]	4 [2.0]	6 [3.2]	1 [3.0]	3 [2.3]	1 [4.0]
Subcapsular, Hyperplasia	46 [2.0]	46 [1.8]	45 [1.9]	44 [2.0]	49 [1.7]	47 [1.7]
Adrenal Medulla	(46)	(45)	(43)	(46)	(47)	(46)
Hyperplasia						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Islets, Pancreatic	(47)	(46)	(46)	(48)	(49)	(46)
Hyperplasia	2 [1.0]	3 [1.0]	4 [1.3]	1 [2.0]	3 [1.0]	4 [1.5]
Infiltration Cellular, Lymphocyte	1 [1.0]					
Parathyroid Gland	(45)	(44)	(40)	(38)	(40)	(36)
Cyst			1 [1.0]			
Hyperplasia						1 [2.0]
Hypertrophy						
Infiltration Cellular, Lymphocyte						
Pituitary Gland	(46)	(44)	(44)	(46)	(49)	(45)
Hemorrhage			1 [4.0]			
Pars Distalis, Angiectasis	1 [2.0]	1 [3.0]	1 [1.0]	2 [1.5]	1 [1.0]	
Pars Distalis, Cyst	1 [2.0]	2 [2.0]	6 [2.2]	3 [1.7]	2 [3.0]	2 [1.5]
Pars Distalis, Hyperplasia	10 [2.2]	10 [2.1]	7 [1.9]	10 [1.8]	11 [2.3]	6 [2.3]
Rathke's Cleft, Dilatation						
Thyroid Gland	(47)	(46)	(46)	(47)	(50)	(46)
Cyst	1 [2.0]				1 [2.0]	
Ectopic Thymus					1	
Infiltration Cellular, Lymphocyte	4 [1.0]		1 [1.0]	2 [1.0]		
Inflammation, Chronic Active						
Polyarteritis						
C-cell, Hyperplasia				1 [1.0]		
Follicle, Degeneration	9 [1.3]	4 [1.5]	7 [1.0]	8 [1.4]	4 [1.3]	6 [1.5]
Follicular Cell, Hyperplasia			1 [1.0]	1 [1.0]	2 [2.5]	
Follicular Cell, Hypertrophy					1 [2.0]	
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(1)	(2)	(1)	(1)	(2)	(0)
Hemorrhage				1 [4.0]		
Infiltration Cellular, Lymphocyte				1 [4.0]		
Abdominal, Fibrosis						
Abdominal, Inflammation, Chronic Active						
Abdominal, Keratin Cyst						
Fat, Necrosis	1 [4.0]					
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(46)	(43)	(44)	(44)	(49)	(44)
Atrophy	2 [3.0]			1 [4.0]		1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Degeneration Inflammation, Suppurative	39 [3.8]	41 [3.8]	41 [3.7]	42 [3.8]	45 [3.8]	41 [3.7]
Ovary	(47)	(45)	(45)	(48)	(50)	(43)
Angiectasis		1 [2.0]				
Atrophy	44 [3.3]	39 [3.1]	44 [3.2]	39 [3.1]	42 [3.1]	36 [3.3]
Cyst	13 [3.0]	11 [3.7]	14 [3.3]	15 [3.0]	17 [3.3]	13 [3.0]
Cyst Dermoid						
Hematocyst		2		4	1	3
Infiltration Cellular, Lymphocyte		2 [3.0]				
Inflammation, Chronic Active						
Bilateral, Cyst	4 [3.3]	4 [3.3]	3 [3.3]	1 [3.0]	2 [2.0]	3 [2.3]
Fat, Necrosis						1 [4.0]
Germinal Epithelium, Hyperplasia		2 [3.0]				
Parenchymal Cell, Degeneration						
Uterus	(47)	(47)	(46)	(48)	(50)	(46)
Angiectasis			1 [4.0]		1 [2.0]	1 [2.0]
Autolysis						
Hydrometra	6 [4.0]	4 [4.0]	5 [4.0]	6 [4.0]	1 [4.0]	1 [4.0]
Thrombosis			1 [4.0]			
Endometrium, Hyperplasia, Cystic	41 [2.7]	42 [2.7]	38 [2.8]	41 [2.7]	49 [2.8]	41 [2.6]
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(46)	(47)	(46)	(46)	(50)	(46)
Hyperplasia		3 [3.0]	2 [2.0]		3 [2.7]	1 [3.0]
Pigmentation				1 [3.0]		
Lymph Node	(8)	(12)	(5)	(5)	(10)	(9)
Cyst					1 [4.0]	
Hemorrhage		1 [2.0]			1 [4.0]	
Hyperplasia, Lymphoid		1 [2.0]				
Axillary, Autolysis						
Axillary, Hyperplasia, Lymphoid	2 [2.5]		1 [2.0]			
Bronchial, Autolysis						
Iliac, Autolysis						
Lumbar, Autolysis						
Lumbar, Cyst						
Lumbar, Fibrosis					1 [2.0]	
Lumbar, Hyperplasia, Lymphoid	2 [2.5]	1 [2.0]		1 [3.0]	1 [2.0]	2 [1.5]
Lumbar, Infiltration Cellular, Plasma Cell				1 [3.0]		

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Lumbar, Infiltration Cellular, Polymorphonuclear						
Lumbar, Inflammation, Chronic Active						
Lumbar, Polyarteritis						
Mediastinal, Autolysis						
Mediastinal, Hyperplasia, Lymphoid				1 [2.0]		2 [1.5]
Mediastinal, Infiltration Cellular, Plasma Cell						
Pancreatic, Hyperplasia, Lymphoid			1 [3.0]		1 [2.0]	
Renal, Autolysis						
Renal, Hyperplasia, Lymphoid	2 [2.5]	1 [2.0]		1 [3.0]		2 [2.0]
Renal, Infiltration Cellular, Plasma Cell				1 [3.0]		
Renal, Infiltration Cellular, Polymorphonuclear						
Sinus, Dilatation		2 [3.0]				
Lymph Node, Mandibular Autolysis	(47)	(44)	(46)	(48)	(49)	(45)
Erythrophagocytosis		1 [2.0]				
Hyperplasia, Lymphoid	9 [1.8]	9 [1.6]	12 [1.8]	12 [1.6]	16 [1.9]	15 [1.5]
Infiltration Cellular, Plasma Cell						1 [2.0]
Infiltration Cellular, Polymorphonuclear					1 [2.0]	
Pigmentation						
Lymph Node, Mesenteric	(45)	(46)	(45)	(45)	(48)	(46)
Angiectasis	1 [3.0]					1 [2.0]
Autolysis	1 [4.0]					
Cyst			1 [4.0]			
Hematopoietic Cell Proliferation						
Hemorrhage			2 [2.5]	1 [2.0]		
Hyperplasia		1 [3.0]				
Hyperplasia, Lymphoid	16 [1.9]	17 [1.8]	16 [1.6]	21 [2.0]	23 [2.1]	20 [2.0]
Infiltration Cellular, Histiocyte	2 [3.5]	1 [2.0]	2 [3.0]	1 [2.0]	1 [4.0]	1 [2.0]
Infiltration Cellular, Plasma Cell		1 [2.0]	1 [3.0]	3 [2.7]	2 [2.5]	3 [3.3]
Infiltration Cellular, Polymorphonuclear	2 [2.0]		1 [2.0]		2 [1.5]	
Inflammation, Chronic Active				2 [4.0]		
Thrombosis						
Sinus, Dilatation	1 [3.0]		1 [4.0]			
Spleen	(47)	(47)	(46)	(47)	(50)	(48)
Autolysis	1 [4.0]					
Erythrophagocytosis						
Hematopoietic Cell Proliferation	11 [2.5]	13 [3.0]	8 [2.6]	13 [2.5]	17 [2.9]	10 [2.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Hemorrhage						
Hyperplasia, Lymphoid	28 [3.1]	25 [2.7]	25 [2.7]	27 [3.1]	32 [2.9]	31 [2.9]
Necrosis		1 [4.0]				
Pigmentation			1 [2.0]			
Thrombosis						
Thymus	(46)	(42)	(44)	(45)	(47)	(43)
Angiectasis			1 [2.0]			
Atrophy	16 [2.5]	12 [2.7]	13 [2.7]	18 [2.4]	13 [2.9]	15 [2.5]
Autolysis	1 [4.0]					
Hyperplasia, Lymphoid	5 [2.2]	6 [2.2]	12 [2.4]	3 [2.0]	9 [1.4]	7 [2.1]
Mineralization	1 [1.0]					
Fat, Necrosis	1 [4.0]					
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(47)	(46)	(45)	(45)	(50)	(45)
Galactocele					1 [3.0]	
Lactation		1 [2.0]	2 [2.0]			
Metaplasia, Squamous						
Alveolus, Hyperplasia	1 [1.0]	2 [3.5]	1 [3.0]	1 [4.0]	1 [3.0]	
Skin	(48)	(47)	(46)	(48)	(50)	(46)
Fibrosis				1 [2.0]		
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic Active		1 [2.0]				
Ulcer		1 [3.0]				
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone, Femur	(48)	(47)	(47)	(48)	(51)	(48)
Fibro-Osseous Lesion		1 [1.0]	1 [4.0]	1 [2.0]	1 [2.0]	1 [4.0]
Skeletal Muscle	(0)	(0)	(0)	(1)	(1)	(1)
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(47)	(46)	(46)	(47)	(49)	(47)
Compression	1 [1.0]	3 [2.0]	1 [3.0]	1 [4.0]	2 [2.0]	
Degeneration						
Hemorrhage			1 [2.0]			

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)



Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Brain, Cerebellum Hemorrhage Infiltration Cellular, Lymphocyte Vacuolization Cytoplasmic Meninges, Infiltration Cellular, Lymphocyte Ventricle, Dilatation	(47)	(46)	(46)	(47)	(49)	(47)
Brain, Cerebrum Cyst Epithelial Inclusion Hemorrhage Mineralization Meninges, Infiltration Cellular, Lymphocyte Ventricle, Dilatation	(47)	(46)	(46)	(47)	(49)	(47)
Peripheral Nerve Axon, Degeneration	22 [1.0] 1 [1.0]	22 [1.0]	26 [1.0]	25 [1.0]	25 [1.1]	28 [1.0]
Spinal Cord Degeneration Inflammation, Chronic Active Axon, Degeneration	(0)	(0)	(0)	(0)	(1)	(1)
	(0)	(0)	(0)	(0)	(1)	(1)
<b>RESPIRATORY SYSTEM</b>						
Lung Autolysis Congestion Crystals Hemorrhage Infiltration Cellular, Histiocyte Infiltration Cellular, Lymphocyte Inflammation, Chronic Inflammation, Chronic Active Metaplasia, Osseous Alveolar Epithelium, Hyperplasia Bronchiole, Hyperplasia	(48) 1 [4.0] 3 [3.0] 1 [2.0] 4 [2.8] 14 [1.6]	(47) 1 [4.0] 3 [3.0] 4 [3.0] 13 [1.7]	(46) 1 [4.0] 1 [4.0] 14 [1.5]	(48) 2 [4.0] 2 [4.0] 14 [1.4] 1 [1.0]	(50) 1 [2.0] 16 [1.4]	(48) 2 [3.0] 3 [2.7] 14 [1.3]
Nose Inflammation, Suppurative Posterior To Upper Incisor, Dysplasia	(48)	(47)	(46)	(48)	(51)	(46)
		1 [3.0]				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(46)	(45)	(46)	(46)	(49)	(45)
Cataract	1 [1.0]	1 [2.0]	1 [1.0]	1 [1.0]	1 [1.0]	1 [2.0]
Degeneration						
Inflammation, Chronic Active						
Metaplasia, Squamous						
Bilateral, Cataract		1 [1.0]				1 [1.0]
Cornea, Inflammation, Chronic Active	1 [2.0]	1 [1.0]		1 [1.0]		1 [1.0]
Cornea, Necrosis	1 [2.0]					
Cornea, Ulcer						
Retina, Degeneration						
Harderian Gland	(46)	(47)	(46)	(47)	(50)	(46)
Cyst					1 [2.0]	
Infiltration Cellular, Lymphocyte	6 [1.0]	8 [1.0]	6 [1.0]	4 [1.0]	4 [1.3]	2 [1.5]
Inflammation, Chronic						
Inflammation, Chronic Active	1 [4.0]					1 [4.0]
Acinus, Degeneration				1 [2.0]	1 [1.0]	
Acinus, Hyperplasia						
Epithelium, Hyperplasia						
<b>URINARY SYSTEM</b>						
Kidney	(46)	(46)	(46)	(46)	(50)	(46)
Amyloid Deposition			1 [4.0]			
Hemorrhage			1 [4.0]			
Hyaline Droplet	1 [3.0]	2 [3.0]		1 [3.0]	1 [4.0]	2 [3.5]
Hydronephrosis			1 [4.0]			
Hyperplasia, Lymphoid						
Infiltration Cellular, Lymphocyte	12 [1.3]	16 [1.3]	15 [1.6]	16 [1.3]	17 [1.1]	13 [1.2]
Inflammation, Chronic Active						
Metaplasia, Osseous	3 [2.0]		3 [1.7]	1 [2.0]	2 [1.5]	1 [1.0]
Nephropathy	25 [1.2]	27 [1.2]	23 [1.3]	18 [1.1]	23 [1.1]	26 [1.2]
Polyarteritis						
Adventitia, Inflammation, Chronic Active			1 [4.0]			
Adventitia, Fat, Necrosis			1 [4.0]			
Urinary Bladder	(46)	(46)	(46)	(46)	(49)	(45)
Edema		1 [3.0]				
Infiltration Cellular, Lymphocyte	20 [1.2]	19 [1.1]	21 [1.1]	22 [1.2]	26 [1.1]	24 [1.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZT-H to 0	AZT-M to 0	AZT-L to 0	AZT-H/3TC-H to 0	AZT-M/3TC-M to 0	AZT-L/3TC-L to 0
Inflammation, Chronic Active Polyarteritis Lumen, Dilatation		1 [3.0]				1 [3.0]

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
<b>Disposition Summary</b>						
Animals Initially in Study	49	48	48	26	49	50
Early Deaths						
Moribund Sacrifice	5	7	12	4	3	8
Natural Death	4	2	2	1	1	5
Survivors						
Moribund Sacrifice		2		2	5	4
Natural Death					1	
Terminal Sacrifice	39	34	31	16	37	30
Harvest	1	3	3	3	2	3
Animals Examined Microscopically	49	48	48	26	49	50

ALIMENTARY SYSTEM

Esophagus	(48)	(47)	(47)	(25)	(48)	(49)
Gallbladder	(45)	(45)	(45)	(25)	(47)	(46)
Cyst			1 [1.0]			
Degeneration, Hyaline				1 [3.0]		
Infiltration Cellular, Lymphocyte				1 [1.0]		1 [1.0]
Inflammation, Chronic						
Intestine Large, Cecum	(45)	(46)	(45)	(25)	(47)	(45)
Hyperplasia, Lymphoid	1 [2.0]	3 [2.0]			2 [2.0]	3 [2.0]
Serosa, Hyperplasia						
Intestine Large, Colon	(45)	(46)	(46)	(25)	(47)	(46)
Intestine Large, Rectum	(45)	(46)	(46)	(25)	(47)	(46)
Hyperplasia, Lymphoid						
Intestine Small, Duodenum	(45)	(46)	(46)	(25)	(47)	(45)
Diverticulum						
Intestine Small, Ileum	(45)	(46)	(46)	(25)	(47)	(45)
Hyperplasia, Lymphoid						
Inflammation, Chronic Active						
Intestine Small, Jejunum	(46)	(46)	(46)	(25)	(47)	(45)
Hyperplasia, Lymphoid						2 [1.5]
Epithelium, Hyperplasia						1 [2.0]
Liver	(47)	(47)	(46)	(26)	(48)	(50)
Angiectasis		1 [2.0]				2 [2.0]
Autolysis				1 [4.0]	1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Basophilic Focus	7	4	3	1	2	1
Basophilic Focus, Multiple						
Clear Cell Focus						
Congestion						
Cyst			1 [2.0]		1 [2.0]	
Cyst Multilocular			1 [4.0]			
Deformity	1					
Eosinophilic Focus		1		1	3	
Eosinophilic Focus, Multiple						
Fatty Change		1 [4.0]				
Hematocyst						
Hematopoietic Cell Proliferation			2 [1.5]		2 [1.0]	2 [2.5]
Hemorrhage						
Hepatodiaphragmatic Nodule						
Infiltration Cellular, Histiocyte						
Infiltration Cellular, Lymphocyte	16 [1.3]	12 [1.3]	13 [1.2]	6 [1.3]	15 [1.2]	13 [1.1]
Inflammation, Chronic Active	3 [1.3]		4 [1.0]	4 [1.3]	7 [1.3]	1 [2.0]
Mineralization						
Mixed Cell Focus	1	1		1	1	1
Necrosis	1 [2.0]	1 [2.0]	1 [2.0]		3 [2.3]	3 [2.0]
Tension Lipidosis	9 [1.6]	10 [1.2]	7 [1.4]	3 [2.0]	5 [1.2]	6 [1.5]
Vacuolization Cytoplasmic	10 [1.6]	24 [1.8]	26 [1.4]	11 [1.3]	25 [1.9]	19 [1.6]
Mesentery	(3)	(8)	(1)	(5)	(7)	(7)
Cyst						
Hematocyst						
Hemorrhage						1 [2.0]
Infiltration Cellular, Lymphocyte					1 [3.0]	
Fat, Necrosis	3 [4.0]	8 [3.6]	1 [4.0]	5 [3.4]	5 [4.0]	5 [3.4]
Pancreas	(47)	(46)	(45)	(25)	(46)	(47)
Cyst			1 [4.0]		2 [1.5]	
Cytoplasmic Alteration						1 [2.0]
Edema						
Infiltration Cellular, Lymphocyte	14 [1.4]	14 [1.3]	20 [1.3]	10 [1.3]	14 [1.1]	19 [1.3]
Inflammation, Chronic Active						
Mineralization	1 [1.0]					
Necrosis						
Acinus, Degeneration	3 [1.0]		1 [2.0]	2 [1.5]	2 [3.0]	3 [3.7]
Duct, Dilatation						1 [3.0]
Fat, Necrosis						
Salivary Glands	(46)	(47)	(47)	(25)	(47)	(47)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Infiltration Cellular, Lymphocyte Polyarteritis	38 [1.3]	36 [1.5]	33 [1.4]	21 [1.5]	40 [1.5]	36 [1.7] 1 [2.0]
Acinus, Degeneration						
Stomach, Forestomach	(47)	(46)	(46)	(25)	(47)	(47)
Hyperkeratosis						
Hyperplasia		1 [3.0]				
Inflammation, Chronic Active			1 [2.0]			
Keratin Cyst		1				
Ulcer		1 [2.0]				1 [2.0]
Epithelium, Hyperplasia	4 [2.0]	1 [2.0]	3 [1.7]		1 [2.0]	1 [2.0]
Stomach, Glandular	(46)	(46)	(46)	(25)	(47)	(46)
Degeneration, Hyaline						
Infiltration Cellular, Lymphocyte						
Inflammation, Chronic Active						
Mineralization						
Epithelium, Hyperplasia			1 [3.0]			
<b>CARDIOVASCULAR SYSTEM</b>						
Blood Vessel	(48)	(47)	(47)	(25)	(48)	(50)
Heart	(49)	(47)	(46)	(25)	(48)	(50)
Cardiomyopathy	1 [1.0]			1 [1.0]		1 [3.0]
Inflammation, Suppurative						
Inflammation, Chronic Active		1 [1.0]				
Mineralization						
Necrosis						
Polyarteritis						1 [1.0]
<b>ENDOCRINE SYSTEM</b>						
Adrenal Cortex	(48)	(46)	(45)	(25)	(49)	(48)
Accessory Adrenal Cortical Nodule	1	1	4		1	2
Angiectasis						
Cyst				1 [1.0]	1 [3.0]	
Hypertrophy	1 [3.0]	1 [1.0]				
Vacuolization Cytoplasmic		1 [3.0]	2 [3.0]		2 [3.0]	1 [3.0]
Subcapsular, Hyperplasia	46 [1.9]	46 [1.8]	45 [1.9]	25 [1.8]	47 [1.8]	47 [1.9]
Adrenal Medulla	(44)	(45)	(43)	(25)	(47)	(46)
Hyperplasia	1 [2.0]				1 [2.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Islets, Pancreatic	(47)	(46)	(45)	(25)	(46)	(47)
Hyperplasia	4 [2.3]	4 [1.5]	3 [1.7]		1 [2.0]	
Infiltration Cellular, Lymphocyte						
Parathyroid Gland	(41)	(44)	(38)	(21)	(42)	(42)
Cyst				1 [2.0]		
Hyperplasia	1 [2.0]					
Hypertrophy						
Infiltration Cellular, Lymphocyte	1 [1.0]	1 [2.0]	1 [1.0]	1 [1.0]		
Pituitary Gland	(42)	(46)	(43)	(23)	(45)	(47)
Hemorrhage						
Pars Distalis, Angiectasis	4 [2.0]	1 [2.0]			4 [1.5]	1 [3.0]
Pars Distalis, Cyst	4 [1.5]		1 [3.0]			
Pars Distalis, Hyperplasia	13 [1.9]	7 [2.0]	8 [1.8]	2 [2.0]	11 [1.5]	11 [1.7]
Rathke's Cleft, Dilatation		1 [3.0]				
Thyroid Gland	(47)	(45)	(46)	(25)	(48)	(47)
Cyst	1 [2.0]	1 [2.0]	1 [2.0]		2 [2.0]	1 [2.0]
Ectopic Thymus		1	1 [2.0]		1 [2.0]	
Infiltration Cellular, Lymphocyte	1 [2.0]	3 [1.0]	1 [1.0]	1 [1.0]	1 [1.0]	5 [1.2]
Inflammation, Chronic Active					1 [1.0]	
Polyarteritis				1 [2.0]		1 [2.0]
C-cell, Hyperplasia						
Follicle, Degeneration	9 [1.8]	7 [1.6]	9 [1.7]	7 [1.7]	4 [1.5]	7 [1.1]
Follicular Cell, Hyperplasia	1 [1.0]					
Follicular Cell, Hypertrophy						
<b>GENERAL BODY SYSTEM</b>						
Tissue NOS	(0)	(0)	(1)	(0)	(1)	(2)
Hemorrhage						
Infiltration Cellular, Lymphocyte						
Abdominal, Fibrosis					1 [4.0]	
Abdominal, Inflammation, Chronic Active					1 [4.0]	1 [4.0]
Abdominal, Keratin Cyst						1 [4.0]
Fat, Necrosis						1 [4.0]
<b>GENITAL SYSTEM</b>						
Clitoral Gland	(46)	(46)	(46)	(25)	(47)	(46)
Atrophy		1 [4.0]	1 [4.0]		1 [4.0]	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Degeneration	45 [3.7]	43 [3.8]	42 [3.7]	24 [3.8]	43 [3.7]	42 [3.6]
Inflammation, Suppurative		1 [1.0]		1 [1.0]		
Ovary	(48)	(47)	(46)	(25)	(48)	(47)
Angiectasis						
Atrophy	40 [3.3]	42 [3.4]	38 [3.2]	23 [3.3]	43 [3.3]	40 [3.1]
Cyst	21 [2.9]	20 [2.8]	21 [3.2]	8 [3.0]	19 [2.8]	13 [3.4]
Cyst Dermoid						1 [4.0]
Hematocyst			1			
Infiltration Cellular, Lymphocyte	1 [2.0]	2 [3.0]			1 [3.0]	2 [2.5]
Inflammation, Chronic Active					1 [4.0]	
Bilateral, Cyst	8 [3.3]	2 [2.0]	5 [2.8]	4 [3.5]	2 [2.5]	3 [3.7]
Fat, Necrosis						
Germinal Epithelium, Hyperplasia						
Parenchymal Cell, Degeneration	1 [4.0]					
Uterus	(48)	(46)	(46)	(26)	(48)	(48)
Angiectasis						2 [2.5]
Autolysis				1 [4.0]		
Hydrometra	1 [4.0]	4 [4.0]	1 [4.0]	2 [4.0]	7 [3.9]	6 [4.0]
Thrombosis						
Endometrium, Hyperplasia, Cystic	44 [2.8]	42 [2.8]	44 [2.7]	22 [2.6]	40 [2.6]	42 [2.4]
<b>HEMATOPOIETIC SYSTEM</b>						
Bone Marrow	(48)	(46)	(46)	(25)	(47)	(47)
Hyperplasia	1 [2.0]	1 [2.0]	1 [2.0]	1 [2.0]	2 [2.5]	3 [2.3]
Pigmentation						
Lymph Node	(4)	(5)	(11)	(3)	(6)	(13)
Cyst						
Hemorrhage	1 [3.0]					
Hyperplasia, Lymphoid	1 [2.0]					
Axillary, Autolysis						
Axillary, Hyperplasia, Lymphoid						1 [3.0]
Bronchial, Autolysis						
Iliac, Autolysis						
Lumbar, Autolysis						
Lumbar, Cyst					1 [4.0]	
Lumbar, Fibrosis						
Lumbar, Hyperplasia, Lymphoid						2 [2.5]
Lumbar, Infiltration Cellular, Plasma Cell						1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)



Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Lumbar, Infiltration Cellular, Polymorphonuclear					1 [4.0]	
Lumbar, Inflammation, Chronic Active						1 [2.0]
Lumbar, Polyarteritis						
Mediastinal, Autolysis						
Mediastinal, Hyperplasia, Lymphoid		1 [2.0]				
Mediastinal, Infiltration Cellular, Plasma Cell		1 [2.0]				
Pancreatic, Hyperplasia, Lymphoid						1 [4.0]
Renal, Autolysis						
Renal, Hyperplasia, Lymphoid						2 [3.0]
Renal, Infiltration Cellular, Plasma Cell						
Renal, Infiltration Cellular, Polymorphonuclear						
Sinus, Dilatation	1 [2.0]					
Lymph Node, Mandibular Autolysis	(47)	(47)	(47)	(25)	(48)	(48)
Erythrophagocytosis						
Hyperplasia, Lymphoid	18 [1.8]	18 [1.9]	11 [1.8]	6 [1.7]	14 [1.8]	13 [2.1]
Infiltration Cellular, Plasma Cell	1 [2.0]	1 [2.0]	1 [2.0]			1 [3.0]
Infiltration Cellular, Polymorphonuclear						
Pigmentation	1 [2.0]					
Lymph Node, Mesenteric	(47)	(46)	(46)	(25)	(47)	(48)
Angiectasis		1 [3.0]				
Autolysis						
Cyst						
Hematopoietic Cell Proliferation		1 [2.0]				
Hemorrhage						
Hyperplasia						
Hyperplasia, Lymphoid	18 [2.0]	21 [1.7]	10 [1.8]	11 [2.1]	21 [1.8]	27 [2.1]
Infiltration Cellular, Histiocyte					2 [2.0]	
Infiltration Cellular, Plasma Cell	2 [2.0]	1 [3.0]			1 [3.0]	4 [3.0]
Infiltration Cellular, Polymorphonuclear						
Inflammation, Chronic Active						
Thrombosis						
Sinus, Dilatation		2 [3.0]				
Spleen	(48)	(47)	(47)	(25)	(48)	(50)
Autolysis					1 [4.0]	
Erythrophagocytosis						
Hematopoietic Cell Proliferation	9 [3.0]	15 [2.4]	10 [3.2]	8 [2.1]	9 [3.3]	12 [2.7]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Hemorrhage					1 [4.0]	
Hyperplasia, Lymphoid	30 [3.1]	30 [3.2]	25 [2.7]	14 [2.9]	27 [2.9]	32 [3.2]
Necrosis					1 [4.0]	
Pigmentation						
Thrombosis		1 [3.0]				
Thymus	(40)	(44)	(44)	(25)	(48)	(44)
Angiectasis	1 [2.0]					
Atrophy	6 [2.3]	11 [2.8]	11 [2.5]	7 [3.1]	6 [2.3]	18 [2.7]
Autolysis						
Hyperplasia, Lymphoid	10 [2.0]	10 [2.2]	4 [1.8]	4 [1.8]	13 [2.2]	8 [2.3]
Mineralization						
Fat, Necrosis						
<b>INTEGUMENTARY SYSTEM</b>						
Mammary Gland	(47)	(47)	(47)	(24)	(48)	(47)
Galactocele						
Lactation						1 [2.0]
Metaplasia, Squamous	1 [2.0]					
Alveolus, Hyperplasia	2 [2.0]	1 [2.0]			3 [2.0]	1 [4.0]
Skin	(49)	(47)	(47)	(25)	(48)	(49)
Fibrosis	1 [2.0]					
Infiltration Cellular, Lymphocyte						1 [3.0]
Inflammation, Chronic Active	1 [2.0]					
Ulcer	1 [3.0]					
<b>MUSCULOSKELETAL SYSTEM</b>						
Bone, Femur	(49)	(48)	(48)	(26)	(49)	(50)
Fibro-Osseous Lesion		1 [2.0]	2 [3.0]	1 [3.0]		
Skeletal Muscle	(1)	(2)	(0)	(0)	(0)	(0)
<b>NERVOUS SYSTEM</b>						
Brain, Brain Stem	(47)	(46)	(46)	(25)	(48)	(47)
Compression	2 [2.5]	1 [4.0]			3 [3.0]	2 [2.0]
Degeneration		1 [1.0]				
Hemorrhage						

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Brain, Cerebellum	(47)	(46)	(46)	(25)	(48)	(47)
Hemorrhage						1 [1.0]
Infiltration Cellular, Lymphocyte				1 [1.0]		
Vacuolization Cytoplasmic				1 [1.0]		
Meninges, Infiltration Cellular, Lymphocyte					1 [2.0]	
Ventricle, Dilatation					(48)	(47)
Brain, Cerebrum	(47)	(46)	(46)	(25)		1
Cyst Epithelial Inclusion						1 [1.0]
Hemorrhage						25 [1.0]
Mineralization	19 [1.0]	16 [1.0]	25 [1.0]	5 [1.0]	18 [1.0]	
Meninges, Infiltration Cellular, Lymphocyte					1 [2.0]	
Ventricle, Dilatation		1 [2.0]				
Peripheral Nerve	(1)	(1)	(0)	(0)	(0)	(0)
Axon, Degeneration	1 [1.0]					
Spinal Cord	(1)	(1)	(0)	(0)	(0)	(0)
Degeneration		1 [3.0]				
Inflammation, Chronic Active		1 [4.0]				
Axon, Degeneration	1 [1.0]					
<b>RESPIRATORY SYSTEM</b>						
Lung	(48)	(47)	(46)	(25)	(47)	(50)
Autolysis	1 [4.0]					
Congestion					1 [3.0]	
Crystals	1 [2.0]	2 [3.0]		2 [3.0]	1 [2.0]	1 [2.0]
Hemorrhage		1 [3.0]				
Infiltration Cellular, Histiocyte	1 [2.0]	3 [2.3]	1 [2.0]	2 [3.0]	4 [2.0]	1 [2.0]
Infiltration Cellular, Lymphocyte	13 [1.7]	15 [1.6]	8 [1.3]	4 [1.8]	9 [1.7]	14 [1.4]
Inflammation, Chronic						
Inflammation, Chronic Active		1 [2.0]	1 [1.0]			1 [1.0]
Metaplasia, Osseous						
Alveolar Epithelium, Hyperplasia	1 [1.0]	2 [1.5]	2 [2.0]	1 [1.0]	1 [3.0]	1 [1.0]
Bronchiole, Hyperplasia			1 [2.0]			
Nose	(49)	(47)	(48)	(26)	(47)	(48)
Inflammation, Suppurative			1 [2.0]			
Posterior To Upper Incisor, Dysplasia		1 [3.0]				

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
<b>SPECIAL SENSES SYSTEM</b>						
Eye	(45)	(45)	(45)	(25)	(47)	(45)
Cataract	1 [2.0]	2 [1.5]	1 [1.0]	1 [1.0]	1 [2.0]	1 [4.0]
Degeneration					1 [3.0]	
Inflammation, Chronic Active					1 [2.0]	
Metaplasia, Squamous				1 [2.0]		
Bilateral, Cataract		1 [1.0]	1 [1.0]		1 [1.0]	
Cornea, Inflammation, Chronic Active	1 [3.0]	1 [1.0]	2 [2.0]	1 [1.0]		
Cornea, Necrosis						
Cornea, Ulcer	1 [3.0]		1 [2.0]			
Retina, Degeneration		1 [4.0]				
Harderian Gland	(46)	(45)	(45)	(25)	(46)	(46)
Cyst						1 [4.0]
Infiltration Cellular, Lymphocyte	5 [1.2]	5 [1.0]	5 [1.0]	2 [1.0]	4 [1.0]	4 [1.3]
Inflammation, Chronic						1 [2.0]
Inflammation, Chronic Active		1 [1.0]				1 [1.0]
Acinus, Degeneration						2 [3.5]
Acinus, Hyperplasia				1 [3.0]		
Epithelium, Hyperplasia	1 [2.0]					
<b>URINARY SYSTEM</b>						
Kidney	(47)	(47)	(48)	(25)	(47)	(47)
Amyloid Deposition			1 [4.0]			
Hemorrhage						
Hyaline Droplet	1 [2.0]					2 [3.5]
Hydronephrosis					1 [4.0]	
Hyperplasia, Lymphoid				1 [2.0]		
Infiltration Cellular, Lymphocyte	11 [1.1]	15 [1.3]	15 [1.3]	5 [1.0]	15 [1.2]	7 [1.3]
Inflammation, Chronic Active					1 [4.0]	
Metaplasia, Osseous			1 [1.0]			1 [2.0]
Nephropathy	30 [1.1]	22 [1.3]	19 [1.4]	12 [1.3]	23 [1.2]	30 [1.4]
Polyarteritis						1 [2.0]
Adventitia, Inflammation, Chronic Active						
Adventitia, Fat, Necrosis						
Urinary Bladder	(46)	(46)	(47)	(25)	(47)	(47)
Edema						
Infiltration Cellular, Lymphocyte	21 [1.1]	25 [1.2]	24 [1.3]	10 [1.3]	23 [1.3]	19 [1.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

TDMS No. 20311 - 02

**P18: INCIDENCE RATES OF NON-NEOPLASTIC LESIONS BY ANATOMIC SITE (a) WITH  
AVERAGE SEVERITY GRADES[b]**

Date Report Requested: 06/29/2009

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

---

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	AZTH/3TCH/NVPH/0	AZTM/3TCM/NVPM/0	AZTL/3TCL/NVPL/0	AZTH/3TCH/NFVH/0	AZTM/3TCM/NFVM/0	AZTL/3TCL/NFVL/0
Inflammation, Chronic Active Polyarteritis Lumen, Dilatation						1 [1.0]

---

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE  
FEMALE

SOLVENT to 0

**Disposition Summary**

Animals Initially in Study	64
Early Deaths	
Moribund Sacrifice	7
Natural Death	3
Survivors	
Moribund Sacrifice	6
Natural Death	1
Terminal Sacrifice	45
Harvest	2
Animals Examined Microscopically	64

## ALIMENTARY SYSTEM

Esophagus	(62)
Gallbladder	(60)
Cyst	
Degeneration, Hyaline	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic	
Intestine Large, Cecum	(60)
Hyperplasia, Lymphoid	
Serosa, Hyperplasia	1 [2.0]
Intestine Large, Colon	(60)
Intestine Large, Rectum	(60)
Hyperplasia, Lymphoid	
Intestine Small, Duodenum	(60)
Diverticulum	
Intestine Small, Ileum	(60)
Hyperplasia, Lymphoid	
Inflammation, Chronic Active	1 [2.0]
Intestine Small, Jejunum	(60)
Hyperplasia, Lymphoid	1 [3.0]
Epithelium, Hyperplasia	
Liver	(61)
Angiectasis	
Autolysis	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Basophilic Focus	2
Basophilic Focus, Multiple	
Clear Cell Focus	
Congestion	
Cyst	1 [2.0]
Cyst Multilocular	
Deformity	
Eosinophilic Focus	3
Eosinophilic Focus, Multiple	
Fatty Change	
Hematocyst	
Hematopoietic Cell Proliferation	2 [1.5]
Hemorrhage	
Hepatodiaphragmatic Nodule	
Infiltration Cellular, Histiocyte	1 [2.0]
Infiltration Cellular, Lymphocyte	18 [1.1]
Inflammation, Chronic Active	5 [1.2]
Mineralization	1 [1.0]
Mixed Cell Focus	1
Necrosis	3 [1.3]
Tension Lipidosis	7 [1.4]
Vacuolization Cytoplasmic	32 [1.6]
Mesentery	(8)
Cyst	
Hematocyst	
Hemorrhage	
Infiltration Cellular, Lymphocyte	
Fat, Necrosis	8 [3.4]
Pancreas	(62)
Cyst	1 [2.0]
Cytoplasmic Alteration	
Edema	
Infiltration Cellular, Lymphocyte	23 [1.0]
Inflammation, Chronic Active	
Mineralization	
Necrosis	
Acinus, Degeneration	2 [1.5]
Duct, Dilatation	
Fat, Necrosis	
Salivary Glands	(62)

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Infiltration Cellular, Lymphocyte Polyarteritis	47 [1.7]
Acinus, Degeneration Stomach, Forestomach	(62)
Hyperkeratosis Hyperplasia Inflammation, Chronic Active Keratin Cyst	
Ulcer	1 [2.0]
Epithelium, Hyperplasia	2 [2.5]
Stomach, Glandular Degeneration, Hyaline	(60)
Infiltration Cellular, Lymphocyte Inflammation, Chronic Active Mineralization Epithelium, Hyperplasia	1 [1.0]
<b>CARDIOVASCULAR SYSTEM</b>	
Blood Vessel	(62)
Heart	(63)
Cardiomyopathy Inflammation, Suppurative	1 [4.0]
Inflammation, Chronic Active Mineralization Necrosis Polyarteritis	
<b>ENDOCRINE SYSTEM</b>	
Adrenal Cortex	(61)
Accessory Adrenal Cortical Nodule	6
Angiectasis Cyst	
Hypertrophy	1 [1.0]
Vacuolization Cytoplasmic	3 [3.0]
Subcapsular, Hyperplasia	60 [1.9]
Adrenal Medulla	(60)
Hyperplasia	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)



Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Islets, Pancreatic	(62)
Hyperplasia	1 [2.0]
Infiltration Cellular, Lymphocyte	1 [1.0]
Parathyroid Gland	(54)
Cyst	1 [2.0]
Hyperplasia	
Hypertrophy	1 [2.0]
Infiltration Cellular, Lymphocyte	
Pituitary Gland	(60)
Hemorrhage	
Pars Distalis, Angiectasis	1 [2.0]
Pars Distalis, Cyst	2 [3.0]
Pars Distalis, Hyperplasia	8 [1.5]
Rathke's Cleft, Dilatation	
Thyroid Gland	(59)
Cyst	
Ectopic Thymus	1 [1.0]
Infiltration Cellular, Lymphocyte	2 [2.0]
Inflammation, Chronic Active	
Polyarteritis	
C-cell, Hyperplasia	
Follicle, Degeneration	9 [1.2]
Follicular Cell, Hyperplasia	
Follicular Cell, Hypertrophy	2 [1.5]
<b>GENERAL BODY SYSTEM</b>	
Tissue NOS	(3)
Hemorrhage	
Infiltration Cellular, Lymphocyte	
Abdominal, Fibrosis	
Abdominal, Inflammation, Chronic Active	1 [4.0]
Abdominal, Keratin Cyst	
Fat, Necrosis	
<b>GENITAL SYSTEM</b>	
Clitoral Gland	(60)
Atrophy	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Degeneration Inflammation, Suppurative	55 [3.7]
Ovary	(60)
Angiectasis	
Atrophy	57 [3.3]
Cyst	22 [2.7]
Cyst Dermoid	
Hematocyst	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic Active	
Bilateral, Cyst	3 [3.0]
Fat, Necrosis	
Germinal Epithelium, Hyperplasia	
Parenchymal Cell, Degeneration	
Uterus	(62)
Angiectasis	
Autolysis	
Hydrometra	9 [4.0]
Thrombosis	
Endometrium, Hyperplasia, Cystic	52 [2.8]

## HEMATOPOIETIC SYSTEM

Bone Marrow	(61)
Hyperplasia	2 [2.5]
Pigmentation	
Lymph Node	(15)
Cyst	
Hemorrhage	1 [2.0]
Hyperplasia, Lymphoid	
Axillary, Autolysis	1 [4.0]
Axillary, Hyperplasia, Lymphoid	
Bronchial, Autolysis	1 [4.0]
Iliac, Autolysis	1 [4.0]
Lumbar, Autolysis	1 [4.0]
Lumbar, Cyst	
Lumbar, Fibrosis	
Lumbar, Hyperplasia, Lymphoid	5 [2.6]
Lumbar, Infiltration Cellular, Plasma Cell	1 [2.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Lumbar, Infiltration Cellular, Polymorphonuclear	2 [2.0]
Lumbar, Inflammation, Chronic Active	
Lumbar, Polyarteritis	
Mediastinal, Autolysis	1 [4.0]
Mediastinal, Hyperplasia, Lymphoid	1 [2.0]
Mediastinal, Infiltration Cellular, Plasma Cell	
Pancreatic, Hyperplasia, Lymphoid	
Renal, Autolysis	1 [4.0]
Renal, Hyperplasia, Lymphoid	1 [2.0]
Renal, Infiltration Cellular, Plasma Cell	
Renal, Infiltration Cellular, Polymorphonuclear	1 [2.0]
Sinus, Dilatation	1 [4.0]
Lymph Node, Mandibular	(61)
Autolysis	1 [4.0]
Erythrophagocytosis	1 [3.0]
Hyperplasia, Lymphoid	16 [2.0]
Infiltration Cellular, Plasma Cell	1 [3.0]
Infiltration Cellular, Polymorphonuclear	1 [2.0]
Pigmentation	
Lymph Node, Mesenteric	(60)
Angiectasis	
Autolysis	1 [4.0]
Cyst	
Hematopoietic Cell Proliferation	
Hemorrhage	
Hyperplasia	
Hyperplasia, Lymphoid	20 [2.0]
Infiltration Cellular, Histiocyte	1 [3.0]
Infiltration Cellular, Plasma Cell	1 [3.0]
Infiltration Cellular, Polymorphonuclear	1 [2.0]
Inflammation, Chronic Active	
Thrombosis	1 [4.0]
Sinus, Dilatation	
Spleen	(62)
Autolysis	1 [4.0]
Erythrophagocytosis	1 [4.0]
Hematopoietic Cell Proliferation	14 [3.2]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Hemorrhage	
Hyperplasia, Lymphoid	32 [2.9]
Necrosis	
Pigmentation	
Thrombosis	
Thymus	(55)
Angiectasis	
Atrophy	13 [2.6]
Autolysis	
Hyperplasia, Lymphoid	12 [2.0]
Mineralization	
Fat, Necrosis	
<b>INTEGUMENTARY SYSTEM</b>	
Mammary Gland	(63)
Galactocele	
Lactation	2 [2.5]
Metaplasia, Squamous	
Alveolus, Hyperplasia	2 [3.0]
Skin	(63)
Fibrosis	
Infiltration Cellular, Lymphocyte	
Inflammation, Chronic Active	
Ulcer	
<b>MUSCULOSKELETAL SYSTEM</b>	
Bone, Femur	(64)
Fibro-Osseous Lesion	
Skeletal Muscle	(1)
<b>NERVOUS SYSTEM</b>	
Brain, Brain Stem	(61)
Compression	1 [3.0]
Degeneration	
Hemorrhage	1 [1.0]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Brain, Cerebellum	(62)
Hemorrhage	
Infiltration Cellular, Lymphocyte	
Vacuolization Cytoplasmic	
Meninges, Infiltration Cellular, Lymphocyte	
Ventricle, Dilatation	
Brain, Cerebrum	(62)
Cyst Epithelial Inclusion	
Hemorrhage	
Mineralization	41 [1.0]
Meninges, Infiltration Cellular, Lymphocyte	
Ventricle, Dilatation	
Peripheral Nerve	(1)
Axon, Degeneration	
Spinal Cord	(1)
Degeneration	
Inflammation, Chronic Active	
Axon, Degeneration	
<b>RESPIRATORY SYSTEM</b>	
Lung	(62)
Autolysis	
Congestion	
Crystals	5 [3.6]
Hemorrhage	1 [1.0]
Infiltration Cellular, Histiocyte	8 [2.9]
Infiltration Cellular, Lymphocyte	19 [1.5]
Inflammation, Chronic	
Inflammation, Chronic Active	
Metaplasia, Osseous	1 [1.0]
Alveolar Epithelium, Hyperplasia	3 [2.7]
Bronchiole, Hyperplasia	
Nose	(62)
Inflammation, Suppurative	1 [2.0]
Posterior To Upper Incisor, Dysplasia	

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

C57BL/6N XC3H/HEN MTV-NCTR MICE  
FEMALE

SOLVENT to 0

## SPECIAL SENSES SYSTEM

Eye	(59)
Cataract	
Degeneration	
Inflammation, Chronic Active	
Metaplasia, Squamous	
Bilateral, Cataract	
Cornea, Inflammation, Chronic Active	1 [1.0]
Cornea, Necrosis	
Cornea, Ulcer	
Retina, Degeneration	
Harderian Gland	(60)
Cyst	
Infiltration Cellular, Lymphocyte	7 [1.0]
Inflammation, Chronic	
Inflammation, Chronic Active	
Acinus, Degeneration	
Acinus, Hyperplasia	
Epithelium, Hyperplasia	

## URINARY SYSTEM

Kidney	(62)
Amyloid Deposition	1 [2.0]
Hemorrhage	
Hyaline Droplet	
Hydronephrosis	
Hyperplasia, Lymphoid	
Infiltration Cellular, Lymphocyte	17 [1.2]
Inflammation, Chronic Active	
Metaplasia, Osseous	2 [1.5]
Nephropathy	31 [1.2]
Polyarteritis	
Adventitia, Inflammation, Chronic Active	
Adventitia, Fat, Necrosis	
Urinary Bladder	(60)
Edema	
Infiltration Cellular, Lymphocyte	20 [1.1]

a - Number of animals examined microscopically at site and number of animals with lesion

b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)

Test Type: CHRONIC

AZT/Drug Combinations Transplacental Carcinogenesis Study

Time Report Requested: 16:30:20

Route: IN-UTERO

CAS Number: AIDSTHERAPEU

First Dose M/F: NA / 07/10/03

Species/Strain: MICE/B6C3F1/NCTR

Lab: NCTR

---

C57BL/6N XC3H/HEN MTV-NCTR MICE FEMALE	SOLVENT to 0
Inflammation, Chronic Active Polyarteritis Lumen, Dilatation	1 [3.0]

---

\*\*\* END OF REPORT \*\*\*

a - Number of animals examined microscopically at site and number of animals with lesion  
b - Average severity grade (1-minimal; 2-mild; 3-moderate; 4-marked)